Evidence map›Paper›PMID 42844339›Full record

ReviewNature reviews. Clinical oncology2026

Exercise therapy in cancer prevention and treatment.

Joshua W Bliss, Lee W Jones

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joshua W BlissDivision of Oncology/Hematology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Lee W JonesDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. leejones@coh.org.ORCID http://orcid.org/0000-0002-3716-8793

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leading oncology agencies endorse exercise as a supportive-care adjunct to mitigate acute and late effects of cancer treatment. A parallel corollary line of investigation in 'exercise oncology' has emerged examining whether exercise benefit extends beyond symptom control to therapeutic outcomes. In this Review, we synthesize the current evidence for exercise as an anticancer strategy. In the cancer prevention and post-diagnosis settings in turn, we first review the epidemiological evidence linking exercise with primary cancer risk and disease outcomes after diagnosis. We then summarize data from key clinical trials evaluating the efficacy of structured exercise therapy on clinical end points and on blood-based and tissue-based biomarkers in individuals with or at risk of cancer. Modification of an individual's exposure to exercise can alter the host macroenvironment, leading to changes in distant tissue and/or tumour microenvironments. Such adaptations might alter the efficacy of conventional cancer therapies, and the newest developments in this rapidly expanding field are also reviewed herein. Finally, we outline a translational framework to facilitate continued development of exercise as an anticancer therapeutic modality and a path towards precision exercise oncology.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.